Pertuzumab Plus Trastuzumab and Real-World Standard of Care (SOC) for Patients (pts) with Treatment Refractory Metastatic Colorectal Cancer (mcrc) with HER2 (ERBB2) Amplification (amp) Confirmed by Tumor Tissue or Ctdna Analysis (TRIUMPH, EPOC1602).